Preliminary findings from the phase I study on Orca-T cell therapy with tacrolimus in RIC will be presented at ASH 2023, showcasing its promise.

Formycon AG, in collaboration with its licensing associate Klinge Biopharma GmbH, has declared the submission of the commercial application for FYB203 to the European Medicines Agency.

KRAS G12C inhibitors: Pioneering cancer treatments with a promising future.

Dupixent® considerably cut down on COPD flare-ups in its subsequent effective Phase 3 investigation, hastening its FDA application and affirming its potential as the initial sanctioned biologic treatment for this severe illness.

In biology, a primer is a short single-stranded nucleic acid sequence that serves as a starting point for DNA synthesis.

Sosei Heptares will reclaim complete ownership of GSK4381406*, a ready-for-clinic, unique oral GPR35 stimulant meant for inflamed bowel disorder.

On Dec 11, 2023, new clinical data on zilurgisertib (INCB000928, LIMBER-104), alone or with ruxolitinib for myelofibrosis-related anemia, will be presented at ASH 2023.

Innovent makes announcement: China's National Medical Products Administration has permitted and given precedence in reviewing the new drug application, IBI351 - the first KRAS G12C inhibitor from the country.

A precursor in biology refers to a substance, cell, or cellular component that serves as a predecessor or antecedent for another substance, cell, or cellular component.

Acrotech Biopharma and Evive Biotech have successfully received FDA authorization to use Ryzneuta® (Efbemalenograstim alfa injection) for treating Neutropenia caused by Chemotherapy (CIN).

JAK1 inhibitors: Transforming autoimmune and inflammatory disease treatments, with promising future developments.

EirGenix Inc. has delivered news regarding the receipt of a marketing endorsement from the European Commission for their trastuzumab biosimilar medication (EG12014).